XTL Biopharmaceuticals Ltd.
XTLB.TA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.04M
Close$
Share Statistics
| Market cap | $2.04 Million |
|---|---|
| Enterprise Value | $2.24 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 404.33% |
|---|---|
| Return on Assets | -618.67% |
| Return on Invested Capital | 792.91% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.96 |
| Enterprise Value to EBIT | -1.11 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About X.T.L. Biopharmaceuticals Ltd.
2,020 employees
CEO: Joshua Levine XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, ...